Best practice guidelines for the management of adverse events associated with amphotericin B lipid complex

Expert Opinion on Drug Safety

Volumn 9, Issue 1, 2010, Pages 139-147

  Craddock, Charles ^a,f   Anson, James ^c,f   Chu, Patrick ^c,f   Dodgson, Andrew ^b,f   Duncan, Nick ^a,f   Gomez, Cesar ^d,f   Mehta, Jayesh ^e,f   Sadullah, Shalal ^d,f   Subudhi, Chinari ^a,f   Yin, John Liu ^b,f  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^d JAMES PAGET UNIVERSITY HOSPITAL   (United Kingdom)

^e NORTHWESTERN UNIVERSITY   (United States)

^f SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Amphotericin B; Fungal infections; Guidelines; Lipid complex; Management

Indexed keywords

ACETYLSALICYLIC ACID; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTIHISTAMINIC AGENT; CHLORPHENIRAMINE; CORTICOSTEROID DERIVATIVE; CREATININE; DANTROLENE; DIPHENHYDRAMINE; HYDROCORTISONE; IBUPROFEN; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PETHIDINE;

CHILL; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CRYPTOCOCCOSIS; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FEVER; DRUG INFUSION; DRUG TOLERABILITY; HUMAN; HYDRATION; INFUSION RATE; KIDNEY FUNCTION; LOW DRUG DOSE; LUNG ASPERGILLOSIS; MUCORMYCOSIS; MYCOSIS; NEPHROTOXICITY; NONHUMAN; PRACTICE GUIDELINE; PREMEDICATION; REVIEW; RIGOR; RISK REDUCTION;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY DISEASES; LIPOSOMES; PRACTICE GUIDELINES AS TOPIC;

EID: 74349098643     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330903418430     Document Type: Review

References (38)

1. Mehta J, Kelsey S, Chu P, et al. Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies. Bone Marrow Transplant 1997;20:39-43
2. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26:1383-1396
3. Fleming RV, Kantarjian HM, Husni R, et al. Comparison of amphotericin B lipid complex (ABLC) vs. AmBisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma 2001;40:511-520.
4. Herbrecht R, Auvrignon A, Andrès E, et al. Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients. Eur J Clin Microbiol Infect Dis 2001;20:77-82
5. Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 2000;31:1155-63.
6. Antoniadou A, Dupont B. Lipid formulations of amphotericin B: Where are we today? J Mycolog Med 2005;15:230-238
7. Saliba F, Dubont B. Renal impairment and amphotericin B formulations in patients with invasive fungal infections. Med Mycol 2008;46:97-112
8. Wiley JM, Seibel NL, Walsh TJ. Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections. Pediatr Infect Dis J 2005;24:167-174
9. Furebring M, Oberg G, Sjolin J. Side effects of amphotericin B lipid complex in the Scandinavian population. Bone Marrow Transplant 2000;25:341-343
10. Warnock DW. Trends in the epidemiology of invasive fungal infections. Jpn J Med Mycol 2007;48:1-12
11. Singh N. Trends in the epidemiology of opportunistic fungal infections: Predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 2001;33:1692-1696
12. Eccles M, Freemantle N, Mason J. North of England evidence based guidelines development project: methods of developing guidelines for efficient drug use in primary care. BMJ 1998;316:1232-1235 (Pubitemid 28171343)
13. Bowden R, Ckandrasekar P, White M, et al. A double-blind randomized controlled trial of amphotericin B colloidal dispersion versus amphotericin B for the treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002;35:359-366
14. White M, Bowden R, Sandler E, et al. Randomised double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998;27:296-302
15. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistant fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999;340:764-771 (Pubitemid 29114295)
16. Rogers DP, Pearson MM, Cleary JD, et al. Differential expression of genes encoding immunomodulatory proteins in response to amphotericin B in human mononuclear cells identified by cDNA microarray analysis. J Antimicrob Chemother 2002;50:811-817
17. Cleary JD, Schwartz M, Rogers DP, et al. Effects of amphotericin B and caspofungin on histamine expression. Pharmacotherapy 2003;23:966-973
18. Conti B, Tabarean I, Andrei C, et al. Cytokines and fever. Front Biosci 2004;1:1433-1449
19. Goodwin SD, Cleary JD, Walawander CA, et al. Pretreatment regimens for adverse events related to infusion of Amphotericin B. Clin Infect Dis 1995;20:775-861
20. O'Connor N, Borley A. Prospective audit of the effectiveness of hydrocortisone premedication on drug delivery reactions following amphotericin B lipid complex. Curr Med Res Opin 2009;25:749-754.
21. Paterson DL, David K, Mrsic M, et al. Pre-medication practices and incidence of infusion-related reactions in patients receiving AMPHOTEC: Data from the Patient Registry of Amphotericin B Cholesteryl Sulfate Complex for Injection Clinical Tolerability (PRoACT) registry. J Antimicrob Chemother 2008;62:1392-1400
22. Kuti JL, Kotapati S, Williams P, et al. Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections. Pharmacoeconomics 2004;22:301-310
23. Aguado JM, Lumbreras C, González-Vidal D. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: A pharmacosurveillance study in Spain. Clin Microbiol Infect 2004;10:785-790.
24. Clevenbergh P, Jacobs F, Kentos A. Compassionate use of amphotericin B lipid complex (Abelcet) in life-threatening fungal infections: Report of 30 courses. Clin Microbiol Infect 1998;4:192-198
25. Sharkey P, Graybill J, Johnson E, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996;22:315-321
26. Mattiuzzi GN, Kantarjian H, Faderl S. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer 2004;1:581-589 (Pubitemid 38124777)
27. Martino R, Subirá M, Sureda A, et al. Amphotericin B lipid complex at 3 mg/kg/day for treatment of invasive fungal infections in adults with haematological malignancies. J Antimicrob Chemother 1999;44:569-572
28. Martino R, Cortés M, Subirá M, et al. Efficacy and toxicity of intermediate-dose amphotericin B lipid complex as a primary or salvage treatment of fungal infections in patients with hematological malignancies. Leuk Lymphoma 2005;46:1429-1435
29. Subirà M, Martino R, Gómez L, et al. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies-a randomized, controlled trial. Eur J Haematol 2004;72:342-347
30. Linden P, Williams P, Chan KM. Efficacy and safety of amphotericin B lipid complex injection (ABLC) in solid-organ transplant recipients with invasive fungal infections. Clin Transplantation 2000;14:329-339
31. Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother 2002;49(Suppl 1):37-41 (Pubitemid 34162655)
32. Mayer J, Doubek M, Doubek J, et al. Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: Animal experiments and clinical study. J Infect Dis 2002;186:379-388.
33. Holler B, Omar SA, Farid MD, et al. Effects of fluid and electrolyte management on amphotericin B-induced nephrotoxicity among extremely low birth weight infants. Pediatrics 2004;113:e608-16
34. Echevarria J, Seas C, Cruz M, et al. Oral rehydration solution to prevent nephrotoxicity of amphotericin B. Am J Trop Med Hyg 2006;75:1108-1112
35. Miller CB, Waller EK, Klingemann HG, et al. Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients. Bone Marrow Transplant 2004;33:543-548
36. Wong-Beringer A, Jacobs RA, Guglielmo J. Lipid formulations of amphotericin B: Clinical efficacy and toxicities. Clin Infect Dis 1998;27:603-618
37. Alexander BD, Wingard JR. Study of renal safety in amphotericin B lipid complex-treated patients. Clin Infect Dis 2005;40:S414-21.
38. Larkin JA, Montero JA. Efficacy and safety of amphotericin B lipid complex for zygomycosis. Infect Med 2003;20:201-206